How Common Is Nausea with Wegovy, and What Should You Do About It?

The decision most people are weighing: is this nausea a reason to stop?

Most people starting Wegovy have done some reading and spotted the nausea warning. The real question is rarely "does it happen?" (it clearly does) but "how bad will it get for me, and is it manageable?" That is a fair thing to work through before committing, and the answer is genuinely nuanced.

Trial data from the STEP programme, summarised on the NHS semaglutide medicines page, confirms nausea is classed as "very common" (affecting more than 1 in 10 people). Across the STEP 1 trial, 44% of the semaglutide group reported it versus 16% on placebo, so roughly one in four of those affected would not have felt queasy without the medicine. But "reported at some point during the trial" is different from "felt sick every day". Most instances cluster around dose increases and are transient. Participants who discontinued specifically because of nausea were a much smaller subset.

The graduated titration schedule, which starts at the lowest dose and moves up in steps roughly every four weeks, exists precisely to reduce peak GI intensity. It is worth reading the wider picture on Wegovy's side-effect profile alongside nausea, because the two often co-exist and understanding the pattern helps.

What nausea on Wegovy actually tends to feel like in practice

For most people, nausea with Wegovy feels like a low-level queasiness after eating rather than acute sickness. Eating more slowly, keeping portions smaller, and avoiding heavy or very fatty meals at the same time as a new dose reduces it noticeably for many. A practical habit worth building: before each weekly injection, give yourself thirty seconds to consider when you last ate something rich, timing and portion size are the two dials you can adjust yourself without waiting for an appointment.

Vomiting does occur, though less commonly than nausea alone. If you want to understand the full range of what to expect, you can read about the most common side effects of Wegovy, which covers nausea alongside diarrhoea, constipation, reflux and burping, the GI system is the primary site of semaglutide's side effects, which is consistent with how GLP-1 medicines slow gastric emptying. The discomfort tends to follow a predictable arc: noticeable in the first few days after a dose step, then gradually settling as the body adapts before the next increase.

Duration varies. Some people feel nothing by day four or five; for others it lingers at a low level across the first month at a new dose. There is detailed guidance on how long nausea typically lasts with Wegovy if the timeline is your main concern, and practical steps for managing it are covered on the Wegovy nausea relief page.

When nausea is not ordinary GI adjustment: signs that need medical attention

This is the section to read carefully, because there is an important distinction between normal GI side effects and something that requires prompt medical attention.

In January 2026 the MHRA issued a Drug Safety Update confirming that acute pancreatitis is a known, infrequent but potentially serious risk with GLP-1 medicines including semaglutide. The hallmark is severe abdominal pain that does not ease and may radiate towards the back, sometimes with nausea or vomiting. This is not the same as post-injection queasiness. If you experience pain like that, stop the injection and seek urgent care (call 111 or go to A&E) rather than waiting to see if it settles.

Other patterns worth escalating to your prescriber rather than managing alone: nausea severe enough to prevent you drinking fluids (dehydration risk), symptoms that worsen significantly several weeks into a stable dose rather than improving, or signs of an allergic reaction such as swelling, rash or breathing difficulty. The MHRA Yellow Card service lets you log any suspected reaction; doing so contributes to ongoing safety monitoring for these medicines.

For a broader look at how Wegovy's semaglutide side effects compare, the semaglutide side-effect overview covers the full clinical picture, including rarer events.

How the prescribing process at nume fits into this

Nausea risk is one of the things a prescriber should discuss with you before treatment starts, not as a deterrent, but so you know what to expect and what distinguishes manageable from concerning. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally, the same day you submit it. They consider your full medical picture, not just a BMI figure.

If nausea becomes a problem during treatment, that is precisely what aftercare is for. You can reach our clinical team seven days a week. Treatment details and what is included in our single transparent price (consultation, prescription, delivery and ongoing support) are on the treatments page. If you want to understand how we approach clinical oversight before deciding, the clinical team profile explains who reviews your case.

Wegovy is a prescription-only medicine. Whether nausea is likely to be significant for you, manageable with simple adjustments, or a reason to consider a different approach is a clinical question. Check your eligibility with our prescribers and get those answers as part of the free consultation.